Table 3 Safety outcomes by allocation

		Placebo (n = 129)^a		Vitamin D (n = 127)^b
		No. of events	Proportion of participants with one or more events (%)	No. of events	Proportion of participants with one or more events (%)
Fatal serious adverse event^c		2	2/128 (1.6)	0	0/123 (0.0)
Non-fatal serious adverse event^c		9	9/128 (7.0)	3	3/123 (2.4)
Non-serious adverse event leading to discontinuation of study supplement		0	0/128 (0.0)	0	0/123 (0.0)
Relapse of SAM (complicated or uncomplicated)		4	4/128 (3.1)	3	3/123 (2.4)
Other monitored safety conditions	Hypercalcaemia^d	6	5/128 (3.9)	2	2/123 (1.6)
	Hypervitaminosis D^e	1	1/83 (1.2)	22	22/85 (25.9)
	Hypercalciuria^f	56	50/128 (39.1)	51	44/123 (35.8)

^ano. of participants who took at least one dose of placebo and for whom follow-up data were available for at least one timepoint.
^bno. of participants who took at least one dose of vitamin D and for whom follow-up data were available for at least one timepoint.
^ccauses for each event presented in Table S5, Supplementary Information.
^ddefined as serum albumin-adjusted calcium concentration >2.65 mmol/L.
^edefined as 25(OH)D concentration >220 nmol/L.
^edefined as urinary calcium:creatinine molar ratio >1.00.

Quick links

Search